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treatment.  Conclusion: This study suggests that the prog-
nostic value of the post-radical prostatectomy Gleason score 
is not meaningfully jeopardized by heterogeneous neoadju-
vant hormonal treatment in a routine clinical setting. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Neoadjuvant hormonal treatment of prostate cancer 
leads to cellular changes resulting in a tendency towards 
a more frequent assignment of higher Gleason scores and 
Gleason 5 pattern  [1–3] . Therefore, the German S3 pros-
tate cancer guidelines  [4] and other authors  [3, 5, 6] rec-
ommend not giving a Gleason score to radical prostatec-
tomy specimens after neoadjuvant hormonal manipula-
tions. Some authors, however, used the prostatectomy 
specimen Gleason score assigned after neoadjuvant hor-
monal treatment, nevertheless, for analysis purposes  [7] .
 To our knowledge, there is little data on the actual con-
sequences of the described cellular changes of neoadju-
vant hormonal therapy on the capability of the Gleason 
score to predict outcome. Since the Gleason score is the 
most important prognostic parameter in patients with 
prostate cancer  [4, 8–11] , the absence of the prognostic 
information delivered by the Gleason score makes it dif-
ficult to counsel patients on their mortality risk and on 
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 Abstract 
 Purpose: To evaluate the validity of the Gleason score after 
neoadjuvant hormonal treatment as predictor of disease-
specific mortality after radical prostatectomy.  Patients and 
Methods: A total of 2,880 patients with a complete data set 
and a mean follow-up of 10.3 years were studied; 425 of 
them (15%) had a history of hormonal treatment prior to sur-
gery. The cumulative incidence of deaths from prostate can-
cer was determined by univariate and multivariate compet-
ing risk analysis. Cox proportional hazard models for com-
peting risks were used to study combined effects of the 
variables on prostate cancer-specific mortality.  Results: A 
higher portion of specimens with a history of neoadjuvant 
hormonal treatment were assigned Gleason scores of 8–10 
(28 vs. 17%, p < 0.0001). The mortality curves in the Gleason 
score strata <8 vs. 8–10 were at large congruent in patients 
with and without neoadjuvant hormonal treatment. In pa-
tients with neoadjuvant hormonal treatment, a Gleason 
score of 8–10 was an independent predictor of prostate can-
cer-specific mortality; the hazard ratio was, however, some-
what lower than in patients without neoadjuvant hormonal 
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adjuvant treatment options. Furthermore, retrospective 
series may contain patients with neoadjuvant hormonal 
treatment in whom the validity of postoperatively as-
signed Gleason score may be of concern. In this study, we 
evaluated the impact of neoadjuvant hormonal treatment 
on the validity of the Gleason score determined in the 
prostatectomy specimen as a predictor of prostate can-
cer-specific mortality in a large sample with long-term 
follow-up.
 Patients and Methods 
 Between December 1, 1992, and December 31, 2007, 2,961 pa-
tients consecutively underwent radical prostatectomy at our insti-
tution. Among them, 2,880 had complete information on speci-
men tumour stage, Gleason score, and lymph node status and were 
analyzed in this study. The prostatectomy specimens of patients 
treated before the year 1999 were reevaluated to assign the histo-
pathological tumour stage and the Gleason score to assure data 
completeness and uniformity. Later, the Gleason score was taken 
from the routine histopathological report without reevaluation. 
The following further variables were analyzed beside Gleason 
score, lymph node status and local tumour stage: history of neoad-
juvant hormonal treatment, prostate specific antigen (PSA; only 
considered in patients without neoadjuvant hormonal treatment), 
age,  American Society of Anesthesiologists physical status class 
and Charlson score. All this information was obtained by review 
of the patient charts. Institutional review board approval was ob-
tained.
 Deaths in the presence of uncontrolled prostate cancer were 
considered events concerning disease-specific mortality. The cu-
mulative incidence of deaths from prostate cancer was determined 
by univariate and multivariable competing risk analysis. The uni-
variate analyses were done using SAS macros and Pepe-Mori tests 
 [12, 13] . Cox proportional hazard models for competing risks ac-
cording to Fine and Gray  [14] were used to study the combined 
effects of the variables on prostate cancer-specific mortality. The 
analyses were performed with the Statistical Analysis Systems ver-
sion 9.4 statistical package (SAS Institute, Cary, N.C., USA).
 Results 
 Demographic data of the study sample are shown in 
 table 1 . A higher portion of specimens with a history of 
neoadjuvant hormonal treatment were assigned Gleason 
scores of 8–10 ( table 1 ). A higher portion of patients who 
received neoadjuvant hormonal treatment had serious co-
morbidity, non-organ-confined disease and lymph node 
involvement ( table 1 ). There was a trend towards higher 
prostate cancer-specific mortality that narrowly missed 
the significance level in patients with neoadjuvant hor-
monal treatment compared with patients without such 
treatment ( fig. 1 ). When the patients were stratified by the 
Gleason score in the prostatectomy specimen, there was 
no detectable difference in prostate cancer-specific mor-
tality between patients with and without neoadjuvant hor-
monal treatment ( fig. 2 ). Stratifying the patients with and 
without neoadjuvant hormonal treatment by the Gleason 
score determined in the prostatectomy specimen resulted 
in clearly separated and largely similar cumulative mortal-
ity curves in both subgroups ( fig. 3 ,  4 ). The relationship 
between the histopathological tumour stage and prostate 
cancer-specific mortality in patients with and without 
neoadjuvant hormonal treatment is shown in  figure 5 .
 In the multivariable analysis, extraprostatic disease, 
positive lymph nodes and a prostatectomy specimen Glea-
Table 1.  Demographic data of the study population stratified by the use of neoadjuvant hormonal treatment
Parameter No neoadjuvant 
hormonal treatment
Neoadjuvant 
hormonal treatment
p value
Sample size 2,455 425
Median, mean, age, years 65 (64) 65 (64) 0.2521
Median, mean, follow-up, censored patients, years 9.6 (10.2) 10.4 (11.0) <0.0001
Median, mean, PSA value, ng/ml 7.4 (11.0) Not available
Organ confined, lymph node-negative disease, % 1,662 (68) 258 (61) 0.0048
Positive lymph nodes, % 204 (8) 49 (12) 0.0304
Gleason score 8–10, % 425 (17) 121 (28) <0.0001
ASA class 3, % 404 (16) 89 (21) 0.0234
Charlson score 2 or higher, % 364 (15) 84 (20) 0.0095
Deaths from prostate cancer 97 36
Deaths from competing causes* 328 62
Deaths from unknown causes 7 2
 * Deaths from non-cancer causes, second cancers or unknown causes.
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 Fig. 2. Cumulative prostate cancer-specific mortality stratified by the Gleason score in the prostatectomy speci-
men in patients with and without neoadjuvant hormonal treatment stratified by the Gleason score in the prosta-
tectomy specimen. 
 Fig. 3. Impact of the Gleason score in the prostatectomy specimen on cumulative prostate cancer-specific mor-
tality stratified by the application of neoadjuvant hormonal treatment using 2-sided stratifications. 
 Fig. 1. Cumulative prostate cancer-specific 
mortality in patients with and without neo-
adjuvant hormonal treatment. 
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son score of 8–10 were independent predictors of prostate 
cancer-specific mortality in the whole study sample with 
the Gleason score having the highest hazard ratio ( table 2 ). 
Neoadjuvant hormonal treatment narrowly missed the sig-
nificance level as a predictor of adverse outcome in the mul-
tivariable analysis ( table 2 ). Very similar models were ob-
tained when the analysis was restricted to patients without 
neoadjuvant hormonal treatment ( table 3 ). When the anal-
ysis was restricted to patients with neoadjuvant hormonal 
treatment, extraprostatic disease and a prostatectomy spec-
imen Gleason score of 8–10 were identified as independent 
predictors of prostate cancer-specific mortality, whereas 
the lymph node status narrowly missed the significance 
level in the multivariable analysis ( table 4 ). In patients with 
neoadjuvant hormonal treatment, the hazard ratio of the 
prostatectomy specimen Gleason score was only second af-
ter that of the local disease stage ( table 4 ). In patients with-
out neoadjuvant hormonal treatment in whom prostate-
specific antigen was analyzable, this variable was without 
detectable prognostic impact ( table 3 ).
 Fig. 4. Impact of the Gleason score in the prostatectomy specimen 
on cumulative prostate cancer-specific mortality stratified by 
the application of neoadjuvant hormonal treatment using tree-
sided stratifications. All curves differed significantly from each 
other  (Pepe Mori test p values ranging between 0.0323 and 
<0.0001). 
 Fig. 5. Impact of the histopathological tumour stage cumulative 
prostate cancer-specific mortality stratified by the application of 
neoadjuvant hormonal treatment. In patients without neoadju-
vant hormonal treatment, all curves differed significantly from 
each other with Pepe Mori test p values <0.0001. In patients who 
received neoadjuvant hormonal treatment, the cumulative mortal-
ity curves of patients with extracapsular lymph node-negative dis-
ease and those with lymph node-positive disease did not differ sig-
nificantly (Pepe Mori test p value 0.1023), whereas the comparison 
of the other cumulative mortality curves reached the significance 
level (organ confined versus extracapsular lymph node-negative 
disease: Pepe Mori test p value 0.0021; organ-confined lymph 
node-negative vs. lymph node-positive disease: Pepe Mori test 
p value 0.0006). 
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 Discussion 
 Cellular changes caused by neoadjuvant hormonal 
treatment may falsely upgrade good-risk patients into the 
unfavorable prognostic subgroups with a Gleason score 
of 8–10  [3] . The clinical significance of this upgrading in 
the Gleason score is not yet fully understood  [5] . Such 
upgrading could result in an inflation of the higher risk 
groups and a subsequent apparent decrease of mortality 
in all subgroups (Will Rogers phenomenon  [15] ). How-
ever, in the routine clinical setting of our study, neoadju-
vant hormonal treatment did not discernibly compro-
mise the prognostic value of the Gleason score. Although 
the higher portion of tumours classified as Gleason score 
8–10 and the lower hazard ratio of the Gleason score after 
neoadjuvant hormonal treatment ( table 4 ) actually sug-
Table 2.  Cox proportional hazard models for competing risks predicting prostate cancer-specific mortality in the whole study popula-
tion (n = 2,880, 133 deaths from prostate cancer)
Parameter Full model  Optimal model
hazard ratio 95% CI p value ha zard ratio 95% CI p value
Age (continuous variable, per year increase) 0.999 0.966–1.033 0.9316
Charlson score (continuous variable) 1.118 0.936–1.335 0.2198
ASA 3 (vs. 1–2) 0.933 0.574–1.518 0.7814
Extraprostatic disease (vs. organ confined) 3.431 2.182–5.396 <0.0001 3.424 2.177–5.385 <0.0001
Positive lymph nodes (vs. negative nodes) 2.564 1.752–3.751 <0.0001 2.583 1.768–3.774 <0.0001
Gleason score 8–10 (vs. <8) 3.998 2.672–5.981 <0.0001 4.170 2.808–6.193 <0.0001
Neoadjuvant hormonal treatment (vs. none) 1.461 0.983–2.170 0.0608
Table 3.  Cox proportional hazard models for competing risks predicting prostate cancer-specific mortality in patients without neoad-
juvant hormonal treatment (n = 2,455, 97 deaths from prostate cancer)
Parameter Full model  Optimal model
hazard ratio 95% CI p value haza rd ratio 95% CI p value
Age (continuous variable, per year increase) 1.004 0.965–1.045 0.8429
Charlson score (continuous variable) 1.168 0.950–1.436 0.1414
ASA 3 (vs. 1–2) 0.838 0.478–1.470 0.5379
Extraprostatic disease (vs. organ confined) 3.518 2.104–5.882 <0.0001 3.491 2.093–5.824 <0.0001
Positive lymph nodes (vs. negative nodes) 2.699 1.749–4.164 <0.0001 2.703 1.759–4.153 <0.0001
Gleason score 8–10 (vs. <8) 4.572 2.887–7.241 <0.0001 4.633 2.943–7.293 <0.0001
 Adding prostate-specific antigen as a continuous variable to the analysis was without any detectable effect on the resulting models 
(hazard ratio 0.999 per ng/ml, 95% CI 0.978–1.010, p = 0.8225 in the proportional hazards model with all variables).
Table 4.  Cox proportional hazard models for competing risks predicting prostate cancer-specific mortality in patients with neoadjuvant 
hormonal treatment (n = 425, 36 deaths from prostate cancer)
Parameter Full model  Optimal model
hazard ratio 95% CI p value haz ard ratio 95% CI p value
Age (continuous variable, per year increase) 0.979 0.919–1.043 0.5199
Charlson score (continuous variable) 0.972 0.693–1.364 0.8697
ASA 3 (vs. 1–2) 1.300 0.482–3.508 0.6039
Extraprostatic disease (vs. organ confined) 3.251 1.294–8.164 0.0121 3.682 1.555–8.719 0.0030
Positive lymph nodes (vs. negative nodes) 2.168 0.955–4.924 0.0644
Gleason score 8–10 (vs. <8) 2.561 1.151–5.700 0.0212 3.037 1.416–6.513 0.0043
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gest some inflation of the Gleason score 8–10 subgroup, 
a Gleason score of 8–10 remained a powerful indepen-
dent predictor of prostate cancer mortality ( table 4 ). Fur-
thermore, the cumulative mortality curves in the Gleason 
score subgroups were virtually identical in patients with 
and without neoadjuvant hormonal treatment ( fig.  2 ). 
Since neoadjuvant hormonal treatment was simultane-
ously associated with a selection process (patients with 
poor prognostic features as for instance high PSA, clini-
cally non-organ-confined disease or high tumour volume 
are more likely to receive such treatment,  table 1 ) illus-
trated by a trend towards increased prostate cancer mor-
tality in patients who had received neoadjuvant hormon-
al treatment in this study,  figure 1 ,  table 2 , it is conceivable 
that the effect of Gleason score upgrading caused by neo-
adjuvant hormonal treatment (thus apparently decreas-
ing mortality in high risk patients) was at least partially 
compensated by this selection-related enrichment of 
poor risks.
 Neoadjuvant hormonal treatment failed to provide 
a  survival benefit after radical prostatectomy  [4, 8] . 
Whereas the guidelines of the European Association of 
Urology generally discourages neoadjuvant hormonal 
treatment prior to radical prostatectomy  [8] , the German 
S3 guidelines on diagnostics and treatment of prostate 
cancer  [4] refers to the limited knowledge on neoadjuvant 
hormonal treatment in patients with locally advanced 
disease and does not completely rule out this option in 
this situation. The German S3 guidelines underline, how-
ever, the adverse impact of such treatment on the histo-
pathological workup and prognostic stratification  [5] . 
Currently, the prognostic evaluation of patients who re-
ceived neoadjuvant hormonal treatment relies only on 
the anatomical tumour stage and the margin status, fac-
tors that may be influenced by neoadjuvant hormonal 
treatment as well as the Gleason score  [8, 16, 17] . Neoad-
juvant hormonal treatment is occasionally used in multi-
modality approaches for high-risk tumours  [18, 19] . In 
such cases, the additional prognostic information provid-
ed by a Gleason score assignment might be of consider-
able clinical importance in order to tailor further treat-
ment strategies after the removal of the prostate. Current-
ly, counseling of patients who had received neoadjuvant 
hormonal treatment is hindered by the unavailability of 
the most important prognostic parameter and a reduced 
meaningfulness of the remaining factors. This study sug-
gests that assigning the Gleason score regardless of neo-
adjuvant hormonal treatment might supplement the 
prognostic armamentarium in patients undergoing radi-
cal prostatectomy. It could be reasonable to add a ‘y’ sym-
bol to the Gleason score in order to indicate that it was 
assigned after neoadjuvant treatment in the analogy of 
the currently used tumour node metastasis classification 
after neoadjuvant treatment  [20, 21] .
 Long-term neoadjuvant hormonal treatment may 
cause more pronounced effects on the cell architecture. 
In a controlled trial with a homogeneous long-term neo-
adjuvant treatment comparing 12 weeks of neoadjuvant 
cyproterone acetate versus no neoadjuvant treatment  [3] , 
there was a greater difference in the distribution of post-
prostatectomy Gleason scores of 8–10 between patients 
with and without neoadjuvant hormonal treatment (52 
vs. 13%) than in our series (28 vs. 17%). Another random-
ized trial demonstrated that a prolonged neoadjuvant 
treatment (8 months) led to further histopathological dis-
ease regression  [22] . It is likely that a consequent long-
term treatment may produce more marked histopatho-
logical changes than a heterogeneous and partially short-
term and/or low-dose treatment in the routine setting of 
our study.
 We are aware of only one study in the literature ad-
dressing a similar question. Bentley and coworkers inves-
tigated the prognostic significance of the Gleason score in 
116 patients treated with different types of neoadjuvant 
hormonal treatment followed by radical prostatectomy 
 [2] . The authors suggested that the Gleason score re-
mained a significant measure in terms of predicting PSA 
progression after neoadjuvant hormonal treatment but 
did not compare mortality outcomes  [2] .
 Limitations 
 The neoadjuvant hormonal treatment in this study 
was heterogeneous, partially short term and/or low dose 
and no details on the actual duration of treatment were 
available. No details on the biopsy Gleason scores prior to 
neoadjuvant hormonal treatment were available. It can-
not be ruled out with certainty that some cases of neoad-
juvant treatment have been overlooked due to incomplete 
documentation or ignorance of some patients as to the 
sort of tablets or injections given to them prior to surgery. 
Since information on neoadjuvant hormonal treat-
ment may be found at different locations in the patient 
charts and a variety of drugs could be involved, this pa-
rameter is more prone to classification errors as other 
clinical data. It is likely that the pathologists who evalu-
ated the prostatectomy specimens were in most cases not 
aware of the application of neoadjuvant hormonal treat-
ment. It is conceivable that they would come to different 
judgements if they would have been aware of such treat-
ment.
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 Conclusion 
 The Gleason score seems to be a powerful independent 
predictor of prostate cancer mortality despite neoadju-
vant hormonal treatment in a routine clinical setting. Us-
ing the Gleason score despite neoadjuvant hormonal 
treatment as a predictor of mortality taking possible lim-
itations into consideration appears to be reasonable rath-
er than the currently recommended general dispense 
from giving a Gleason score after neoadjuvant hormonal 
treatment.
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